NK cell double take

How Affimed and MD Anderson are boosting NK cell antitumor activity

NK cells are raising interest in immuno-oncology with potential safety benefits and broader activity than their T cell counterparts, but achieving sufficiently high levels of activation is an ongoing challenge. Affimed N.V. (NASDAQ: AFMD) thinks its NK cell-activating antibodies could provide the solution, and has teamed up with the University of Texas MD Anderson Cancer Center to test

Read the full 587 word article

User Sign In